Breast Cancer
News
Lower CTC count IDs indolent MBC disease subset
A CTC count less than 5 per 7.5 mL of blood in MBC patients indicates an indolent disease subset, pooled data from two large cohorts show.
News
FDA expands indication for ribociclib for advanced breast cancer
Approval of the CDK 4/6 inhibitor was expanded to include the treatment of pre/perimenopausal women with HR-positive, HER2-negative, in...
News
FDA approves abemaciclib for advanced breast cancer
The indication for the CDK4/6 inhibitor includes treatment in combination with fulvestrant and as a single agent.
News
HER2 status differed between primary tumor and CTCs in 18.8% of women with MBC
The probability of HER2 status discordance decreased with increasing age, but increased with primary tumors that were hormone-receptor positive,...
Video
VIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017
Expert provides take-home messages on pertuzumab, PARP inhibitors, and CDK4/6 inhibitors.
Video
VIDEO: NCI estimation of MBC numbers a start, but more is needed
SEER data on metastatic breast cancer includes only those diagnosed de novo and not women who were diagnosed following a metastatic recurrence of...
Video
VIDEO: Metastatic Trial Search links MBC patients to relevant trials
CHICAGO – A breast cancer advocate discusses mixed response from physicians and barriers to trial participation faced by patients.